Tyme and JAF Announce Sarcoma Treatment Collaboration
April 06, 2018 08:00 ET
|
Tyme Technologies, Inc.
NEW YORK, April 06, 2018 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ:TYME), a clinical-stage oncology company, today announced that it is collaborating with The Joseph Ahmed Foundation...
Tyme Technologies, Inc. Announces Participation at the H.C. Wainwright Annual Global Life Sciences Conference in Monte Carlo, Monaco on April 8-10, 2018
March 29, 2018 08:00 ET
|
Tyme Technologies, Inc.
NEW YORK, March 29, 2018 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ:TYME) (“Tyme” or the “Company”) announced today that it will be featured as a presenting company at the H. C. Wainwright...
Tyme Announces First Site Open for its Phase II Trial with SM-88 in Pancreatic Cancer
March 27, 2018 08:00 ET
|
Tyme Technologies, Inc.
NEW YORK, March 27, 2018 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ:TYME) (“Tyme” or the “Company”) announced today that the first site for the Phase II clinical trial evaluating SM-88...
FDA Acceptance of IND for Tyme to Begin Phase II Trial in Pancreatic Cancer
March 14, 2018 08:00 ET
|
Tyme Technologies, Inc.
Initial Clinical Sites Expected to Open Over the Coming Weeks NEW YORK, March 14, 2018 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ:TYME) (“Tyme” or the “Company”) announced today that the...
Tyme Technologies Announces Closing of Public Offering of Common Stock
March 08, 2018 08:00 ET
|
Tyme Technologies, Inc.
NEW YORK, March 08, 2018 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ:TYME) (“Tyme” or the “Company”) announced today that, on March 6, 2018, it closed its underwritten public offering of...
Tyme Technologies Announces Pricing of its Offering of 9 Million Shares of Common Stock
March 01, 2018 21:46 ET
|
Tyme Technologies, Inc.
NEW YORK, March 01, 2018 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ:TYME) (the “Company”) announced today that it has priced its underwritten public offering of 9 million shares of its...
Tyme Technologies Announces Offering of Common Stock
February 26, 2018 16:01 ET
|
Tyme Technologies, Inc.
NEW YORK, Feb. 26, 2018 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ:TYME) (the “Company”), a clinical-stage biotechnology company developing cancer therapeutics, today announced that it had...
Tyme Technologies Appoints Tommy G. Thompson to Board of Directors
February 21, 2018 09:00 ET
|
Tyme Technologies, Inc.
NEW YORK, Feb. 21, 2018 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ:TYME), a clinical-stage biotechnology company developing cancer therapeutics, today announced the appointment of former...
Tyme to Present at RBC Capital Markets 2018 Global Healthcare Conference
February 13, 2018 08:00 ET
|
Tyme Technologies, Inc.
NEW YORK, Feb. 13, 2018 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ:TYME), a clinical-stage biotechnology company developing cancer therapeutics, today announced that company management will...
Tyme Announces Interim Phase II Safety and Efficacy Data for SM-88 in Prostate Cancer at 2018 ASCO Genitourinary Cancers Symposium
February 08, 2018 10:00 ET
|
Tyme Technologies, Inc.
92% of Patients Have Maintained Radiographic Progression-Free Survival at a Median of 12 Months Since Biochemical-RecurrenceAll Patients Have Reported Stable Cognitive and Sexual Function on SM-88...